EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients

Cindy Marques iD, Guillaume Moulis, Mickaël Roussotte, Bernard Bonnotte, Jean-François Viallard, Julie Graveleau, Hervé Lobbes iD, Nathalie Costedoat-Chalumeau, Alban Deroux, Delphine Gobert, Antoine Dossier, Laurent Gilardin iD und 6 weitere

American Journal of Hematology · 2025-11 · 100 (11) · 1972-1982

DOI: 10.1002/ajh.70052 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 06.10.2025. Verfasst von Cindy Marques und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antiphospholipid Syndrome, Purpura, Thrombocytopenic, Idiopathic, Receptors, Thrombopoietin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Only few data are available regarding the efficacy and safety of thrombopoietin receptor agonists (TPO‐RAs) for treating systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)‐associated immune thrombocytopenia (ITP). We retrospectively assessed the efficacy and safety of TPO‐RAs in 80 adults with ITP in three subgroups: (1) 37 patients with definite or incomplete SLE and no antiphospholipid antibodies (APAs), (2) 27 patients with definite or incomplete SLE associated with APAs and no history of arterial or venous thrombotic events (TEs) and (3) 16 patients with APS. In total, 39 (48.8%) patients received eltrombopag, 14 (17.5%) romiplostim and 27 (33.8%) both TPO‐RAs sequentially. The overall response of ITP was 78.8%. In total, 17 (21.3%) patients had 21 TEs (7 venous and 14 arterials, including 3 catastrophic APS); 3 were fatal. The rate of TEs was 8.1% in the SLE or lupus without APAs group, 22.2% in the SLE or lupus with APAs group and 50% in the APS group. In 12 patients, TPO‐RAs were continued after TE onset, combined with an anticoagulant ( n = 12) and/or an antiplatelet agent ( n = 3). Only one TE relapse occurred in the nine patients with TPO‐RAs maintained and combined with an anticoagulant after TE. TPO‐RAs may be effective safe in ITP associated with SLE and no APAs. Their use should be carefully considered in the presence of thrombotic risk factors and/or APA positivity and should be avoided in patients with definite APS. When a TE occurs, risk of relapse is low with maintenance of the TPO‐RA combined with anticoagulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntiphospholipid SyndromePurpura, Thrombocytopenic, IdiopathicReceptors, ThrombopoietinThrombosisRetrospective StudiesRisk FactorsFranceHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overAnticoagulantsPlatelet Aggregation InhibitorsThrombopoietinBenzoatesReceptors, FcHydrazinesRecombinant Fusion ProteinsPyrazoles

Stichwörter der Autor:innen

antiphospholipid antibody syndromeimmune thrombocytopeniathrombopoietin

Substanzen

Receptors, ThrombopoietineltrombopagromiplostimAnticoagulantsPlatelet Aggregation InhibitorsThrombopoietinBenzoatesReceptors, FcHydrazinesRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France.
  • Department of Internal Medicine & Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse, France.
  • Department of Internal Medicine, Hôpital Universitaire Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
  • Department of Internal Medicine, Centre Hospitalier Universitaire de Dijon, Dijon, France.
  • Département de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire Haut Lévêque, Université de Bordeaux, Pessac, France.
  • Department of Internal Medicine, Centre Hospitalier Universitaire de Nantes, Nantes, France.

ORCID-Profile: Cindy Marques, Hervé Lobbes, Laurent Gilardin, Matthieu Mahévas, Marc Michel

Zitieren

APA

Marques, C., Moulis, G., Roussotte, M., Bonnotte, B., Viallard, J. F., Graveleau, J., Lobbes, H., Costedoat-Chalumeau, N., Deroux, A., Gobert, D., Dossier, A., Gilardin, L., Lambotte, O., Dufrenoy, M., Mahévas, M., Michel, M., Sève, P., & Godeau, B. (2025). Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients. American Journal of Hematology, 100(11), 1972-1982. https://doi.org/10.1002/ajh.70052

Vancouver

Marques C, Moulis G, Roussotte M, Bonnotte B, Viallard JF, Graveleau J, et al. Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients. American Journal of Hematology. 2025;100(11):1972-1982. doi:10.1002/ajh.70052

BibTeX
@article{Marques2025,
  author = {Marques, Cindy and Moulis, Guillaume and Roussotte, Mickaël and Bonnotte, Bernard and Viallard, Jean-François and Graveleau, Julie and Lobbes, Hervé and Costedoat-Chalumeau, Nathalie and Deroux, Alban and Gobert, Delphine and Dossier, Antoine and Gilardin, Laurent and Lambotte, Olivier and Dufrenoy, Mylène and Mahévas, Matthieu and Michel, Marc and Sève, Pascal and Godeau, Bertrand},
  title = {Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {11},
  pages = {1972--1982},
  doi = {10.1002/ajh.70052}
}
Kostenlos starten →